FDA to trial malaria drugs Chloroquine and Hydroxychloroquine for COVID-19

FDA to trial malaria drugs Chloroquine and Hydroxychloroquine for COVID-19

FDA to trial malaria drugs Chloroquine and Hydroxychloroquine for COVID-19

The U.S. Food and Drug Administration (FDA) this week provided the necessary authorization for clinical trials of chloroquine and hydroxychloroquine for the treatment of the novel coronavirus. These two drugs have been claimed by President Donald Trump to be a potential treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which causes COVID-19 disease. To date, there has been no conclusive proof regarding the safety and efficacy of these drugs in COVID-19 cases, say officials.